anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Glioblastoma (GBM), an incurable primary brain tumor, typically requires surgical intervention followed by chemoradiation; however, recurrences remain fatal. Our previous work demonstrated that a nanomedicine hydrogel (GemC12-LNC) delays recurrence when administered post-surgery. However, tumor debulking also triggers time-dependent immune reactions that promote recurrence at the resection cavity borders. We hypothesized that combining the hydrogel with an immunomodulatory drug could enhance therapeutic outcomes. A thorough characterization of the post-surgical microenvironment (SMe) is crucial to guide combinatorial approaches.In this study, we performed cellular resolution imaging, flow cytometry and spatial hyperplexed immunofluorescence imaging to characterize the SMe in a syngeneic mouse model of tumor resection. Owing to our dynamic approach, we observed transient opening of the blood-brain barrier (BBB) during the first week after surgery. BBB permeability post-surgery was also confirmed in GBM patients. In our murine model, we also observed changes in immune cell morphology and spatial location post-surgery over time in resected animals as well as the accumulation of reactive microglia and anti-inflammatory macrophages in recurrences compared to unresected tumors since the first steps of recurrence growth. Therefore we investigated whether starting a systemic treatment with the SMAC mimetic small molecule (GDC-0152) directly after surgery would be beneficial for enhancing microglial anti-tumoral activity and decreasing the number of anti-inflammatory macrophages around the GemC12-LNC hydrogel-loaded tumor cavity. The immunomodulatory effects of this drug combination was firstly shown in patient-derived tumoroids. Its efficacy was confirmed in vivo by survival analysis and correlated with reversal of the immune profile as well as delayed tumor recurrence.This comprehensive study identified critical time frames and immune cellular targets within the SMe, aiding in the rational design of combination therapies to delay recurrence onset. Our findings suggest that post-surgical systemic injection of GDC-0152 in combination with GemC12-LNC local treatment is a promising and innovative approach for managing GBM recurrence, with potential for future translation to human patient.
ClLOX, is located on chromosome 2 and encodes a lipoxygenase gene, which induced watermelon powdery mildew resistance by inhibiting pathogen spread. Powdery mildew is one of the most severe fungal diseases reducing yield and quality of watermelon (Citrullus lanatus L.) and other cucurbit crops. Genes responsible for powdery mildew resistance in watermelon are highly valuable. In this study, we first identified the QTL pm-lox for powdery mildew resistance in watermelon, located within a 0.93 Mb interval of chromosome 2, via XP-GWAS method using two F2 populations. The F2:3 families from one of the F2 populations were then used for fine-mapping the pm-lox locus into a 9,883 bp physical region between 29,581,906 and 29,591,789, containing only two annotated genes. Of these, only ClG42_02g0161300 showed a significant differential expression between the resistant and susceptible lines after powdery mildew inoculation based on RNA sequencing (RNA-seq) and qRT-PCR analysis, and is designated ClLOX. Derived Cleaved Amplified Polymorphic Sequence (dCAPs) markers were developed and validated. In addition, our tests showed that the resistance was anti-spread rather than anti-infection of the pathogen. This study identified a new resistance gene (ClLOX), provided insights into the mechanism of powdery mildew resistance, and developed a molecular marker for watermelon breeding.
The present invention relates to a topical gel with antiseptic and healing functions from the Leaf of Seaw (still to be identified) and Donkey Ear (Elephantopus Mollis) as an alternative in the treatment of wounds, infections, and minor irritations, thus aiming to provide an efficient alternative in traditional medicine. The gel comprises ketone extracts processed (at 65°C for four hours) from 30gr. of leaves of both plants. Said leaves concentrate and resuspend in distilled water at concentrations of up to 1000 mg/ml and integrate into a water-based gel, subsequently tested on Staphylococcus Aureus and Candida Utilis by plaque and sensor-disc casting technique, throwing a high antimicrobial effectiveness on Staphylococcus Aureus. In addition, the gel is determined as an antiseptic agent at four mg/ml and a high bioavailability (distribution in the skin). Further, it comprises 70% extract of plants (active substance), 25% Carbopol, 2% Triethanolamine (providing consistency), and 3% gl ycerin (providing moisture). Finally, it applies to four mg/ml extract of both plants, thus providing high effectiveness and low concentration, making its origin costs economical and profitable.
Chronic obstructive pulmonary disease (COPD) and lung cancer represent formidable challenges in global health, characterized by intricate pathophysiological mechanisms and multifaceted disease progression. This comprehensive review integrates insights from diverse perspectives to elucidate the intricate roles of long non-coding RNAs (lncRNAs) in the pathogenesis of COPD and lung cancer, focusing on their diagnostic, prognostic, and therapeutic implications. In the context of COPD, dysregulated lncRNAs, such as NEAT1, TUG1, MALAT1, HOTAIR, and GAS5, emerge as pivotal regulators of genes involved in the disease pathogenesis and progression. Their identification, profiling, and correlation with the disease severity present promising avenues for prognostic and diagnostic applications, thereby shaping personalized disease interventions. These lncRNAs are also implicated in lung cancer, underscoring their multifaceted roles and therapeutic potential across both diseases. In the domain of lung cancer, lncRNAs play intricate modulatory roles in disease progression, offering avenues for innovative therapeutic approaches and prognostic indicators. LncRNA-mediated immune responses have been shown to drive lung cancer progression by modulating the tumor microenvironment, influencing immune cell infiltration, and altering cytokine production. Their dysregulation significantly contributes to tumor growth, metastasis, and chemo-resistance, thereby emphasizing their significance as therapeutic targets and prognostic markers. This review summarizes the transformative potential of lncRNA-based diagnostics and therapeutics for COPD and lung cancer, offering valuable insights into future research directions for clinical translation and therapeutic development.
The initial stages of acute pancreatitis (AP) are characterized by a significant event - acinar ductal metaplasia (ADM). This process is a crucial feature of both acute and chronic pancreatitis, serving as the first step in the development of pancreatic cancer. Ion channels are integral transmembrane proteins that play a pivotal role in numerous biological processes by modulating ion flux. In many diseases, the expression and activity of ion channels are often dysregulated. Metal ions, including calcium ions (Ca2+), ferrous ions (Fe2+), and Copper ions (Cu2+), assume a distinctive role in cellular metabolism. These ions possess specific biological properties relevant to cellular function. However, the interactions among these ions exacerbate the imbalance within the intracellular environment, resulting in cellular damage and influencing the progression of AP. A more in-depth investigation into the mechanisms by which these ions interact with acinar cells is essential for elucidating AP's pathogenesis and identifying novel therapeutic strategies. Currently, treatment for AP primarily focuses on pain relief, complications prevention, and prognosis improvement. There are limited specific treatments targeting acinous cell dedifferentiation or ion imbalance. This study aims to investigate potential therapeutic strategies by examining ion crosstalk within acinar cells in the context of acute pancreatitis.
BACKGROUND: Vancomycin-induced bleeding has been reported, attributed to the mechanism of immune thrombocytopenia. A rare case of vancomycin-induced gastrointestinal hemorrhage in a young patient with no underlying disease, receiving intravenous vancomycin for methicillin-resistant Staphylococcus aureus (MRSA) infection, is presented. This occurrence occurred without thrombocytopenia. Relevant cases reported in the literature were also reviewed.
CASE PRESENTATION: A 34-year-old male patient presented with maxillofacial multiple spaces infection accompanying left temporal abscess, bilateral lung abscesses. Culture results from both blood and secretion indicated that the infection was caused by MRSA. The patient received standard-dose vancomycin (1 g q12h intravenously guttae) for treatment. On the 5th day of therapy, he presented with bright red blood in his stool; however, vancomycin treatment was continued. By the 9th day, a decrease in hemoglobin level to 76 g/L and a platelet (PLT) count of 424 × 109/L raised concerns about gastrointestinal hemorrhage. The hemoglobin level decreased to 62 g/L on day 12. Due to the high tissue concentration of linezolid, administration of linezolid at a dose of 600 mg q12h intravenously guttae commenced on the 13th day as an alternative to vancomycin(D13-D17). Subsequently, on the 17th day, there was an improvement in hemoglobin level to 78 g/L. However, despite treatment with linezolid, the patient's fever showed no significant improvement, prompting a switch back to vancomycin at a dosage of 1 g q12h intravenously guttae(D18-D22). On the 21st day, there was a recurrence of gastrointestinal hemorrhage, accompanied by a hemoglobin level of 42 g/L and a PLT count of 224 × 109/L. Gastroscopy revealed the presence of a gastroduodenal ulcer. The patient had no prior history of hemorrhoids, gastrointestinal ulcers, liver cirrhosis, or purpura. Prior to admission, he had not been administered non-steroidal anti-inflammatory drugs (NSAIDs) or steroids. During hospitalization, the only medications given were vancomycin, ambroxol and lidocaine. Additional tests ruled out immunological disorders as the cause of gastrointestinal ulcers, and a positive vancomycin rechallenge test indicated an association between vancomycin and bleeding. After discontinuation of vancomycin, no further bleeding occurred. This case highlights a rare occurrence of vancomycin-induced bleeding without thrombocytopenia, classified as "Certain" according to the World Health Organization-Uppsala Monitoring Centre (WHO-UMC) scale for standardized case causality assessment.
CONCLUSION: This case represents the first documented instance of vancomycin-induced bleeding without thrombocytopenia, as confirmed by a positive rechallenge test. This discovery will aid in the early detection of this rare adverse reaction in future cases.
Despite a growing number of studies dedicated to neurofeedback, the underlying cerebral mechanisms (plasticity phenomena underlying neurofeedback training or learning) are very poorly known. In most of the work on stress and anxiety reduction, the neural parameters on which neurofeedback is performed are low frequency waves like alpha waves. But the effects that an alpha-based neurofeedback has on these waves and more generally on the oscillatory behaviour of the networks involved after the neurofeedback sessions, are very little studied.

Thus, the NEURORELAX study aims to clarify the effects on neurofeedback training at the (electro)physiological level (changes in brain responses in terms of frequency of oscillations, power and location of the cerebral sources of these activities) and/or behavioural level (relaxation and reduced susceptibility to anxiety). It will use the Melomind neurofeedback device as built by myBrain Technologies company, which will make it additionally possible to assess feasibility of neurofeedback training with this reduced mobile device comprising of 2 dry electrodes. For these purposes, the investigators will propose a series of auditory neurofeedback training sessions to the participants, accompanied by electrophysiological (EEG) and clinical measures. The level of relaxation of the subjects will be characterized by self-reported questionnaires and by electrophysiological signal measurement.
PURPOSE:A remedy for hepatic diseases, capable of carrying out simultaneously nutrition control of a patient of hepatic diseases who can not particularly orally take a nutrition source, containing two or more of nucleic acid bases of nucleic acid constituent components, nucleosides and nucleotides as active ingredients. CONSTITUTION:A remedy for hepatic diseses containing at least two, preferably 4-6 substance selected from nucleic acid bases (e.g., adenine, hypoxanthine, guanine, etc.) of nucleic acid constituent components, nucleosides (e.g., adenosine, inosine, etc.) and nuclotides (e.g., ATP, AMP, etc.) as active ingredients. A preferable combination of the active ingredients is a molar ratio of inosine: cytidine: GMP: uridine: thymidine=4:4:4:3:1 (molar ratio). Administration form is preferably an injection and powder, solution, etc., for administration through the rectum are also usable. The remedy has remedying effects on hepatic diseases and can carry out maintenance of nitrogen equilibrium and nutrition control.
288,132. Schering-Kahlbaum Akt.- Ges. March 31, 1927, [Convention date]. Medicines for internal use.-A therapeutically active substance is prepared from the anterior lobes of the pituitary body by-treating the fresh or dried glands with an alkaline extraction agent or with Ringer's solution having an alkaline reaction. According to examples (1) fresh glands are finely divided and extracted with Ringer's solution at room temperature or at a temperature between 40 and 50‹ C., the solution is filtered, de-albuminated with colloidal iron hydroxide, and the filtrate concentrated in vacuum; (2) dried glands are treated with N/10 caustic soda lye, the filtrate is acidified with acetic acid, precipitated albumen removed, and the active substance salted out by means of common salt and taken up with water. The Specification as open to inspection under Sect. 91 (3) (a) refers also to the use of physiological extraction agents in general, and contains an additional example according to which dried glands are boiled with 10 per cent baryta solution for four hours and the filtered solution acidified to precipitate the active substance. This subjectmatter does not appear in the Specification as accepted. Specification 208,154 is referred to.
ackground: Behaviour management techniques have an important place in paediatric dentistry. However, alternative methods may be needed if they are found to be ineffective in reducing children's dental anxiety.Aim: This study aimed to evaluate the impact of reading educational books, watching videos and playing mobile games from the child's, dentist's and parent's perspective on children's dental anxiety before treatment.

Methods: A total of 160 patients were randomly assigned to four groups. Anxiety levels of patients in each group were assessed using the Facial Image Scale, the Frankl Behaviour Scale and pulse oximetry. The Corah Dental Anxiety Scale was administered to parents to assess their child's anxiety level. The first group was exposed to the tell-show-do technique, the second group read a book, the third group watched a video and the fourth group played a mobile phone game. The children in each group were then assessed. Anxiety levels were then reassessed using the same scales.
Pediatric Patients

Limited pharmacokinetic data for fludarabine phosphate for injection are available from a published study of children (ages 1 to 21 years) with refractory acute leukemias or solid tumors (Children’s Cancer Group Study 097). When fludarabine phosphate for injection was administered as a loading dose over 10 minutes immediately followed by a 5-day continuous infusion, steady-state conditions were reached early.    


Patients with Renal Impairment

The total body clearance of the principal metabolite 2-fluoro-ara-A correlated with the creatinine clearance, indicating the importance of the renal excretion pathway for the elimination of the drug. Renal clearance represents approximately 40% of the total body clearance. Patients with moderate renal impairment (17 to 41 mL/min/m 2) receiving 20% reduced fludarabine dose had a similar exposure (AUC; 21 versus 20 nM•h/mL) compared to patients with normal renal function receiving the recommended dose. The mean total body clearance was 172 mL/min for normal and 124 mL/min for patients with moderately impaired renal function.
High school graduation is tremendously protective against involvement with crime and violence, as well as against the risk of adult poverty, unemployment, and poor health. Most of the policy and research attention on dropout has focused on the dropout decision itself. Yet dropout is almost always the end point of a longer-term developmental process. For this project the investigators have raised nearly $7 million in external support from the U.S. Department of Education, the National Institutes of Health, and the William T. Grant Foundation to learn more about the relative effectiveness of preventing dropout by trying to re-engage children in school much earlier during their academic careers.

Specifically, this project is motivated by findings from the late University of Chicago sociologist James Coleman indicating that one of the strongest protective factors against school failure for children is having a strong relationship with a pro-social adult - something that far too many children do not currently have, particularly those growing up in distressed family and community environments. The investigators are partnering with other researchers at Northwestern, Duke, and the University of Minnesota to test at large scale the effects of a structured mentoring and monitoring programs called Check \& Connect. To date, the project has completed its pilot year, and starting this academic year will work with nearly 500 elementary and middle school students distributed across 23 CPS schools on the West and South sides of the city. Students will receive Check \& Connect assistance for two academic years total.
All multiple myeloma cell lines examined showed constitutively active IkB kinase (IKK), IkB.alpha. phosphorylation and constitutively active NF-kB. Curcumin, a chemopreventive agent, suppressed constitutive IkB.alpha. phosphorylation through inhibition of IKK activity and downregulated NF-kB. Curcumin also downregulated expression of NF-kB-regulated gene products such as IkB.alpha., Bcl-2, Bcl-xL, cyclin D1 and interleukin-6. Consequently, curcumin suppressed multiple myelona cell proliferation and arrested cells a t the G1/S phase of the cell cycle. Curcumin also induced apoptosis and chemosensitivity to vincristine. Overall, results presented herein provide a molecular basis for the treatment of multiple myelona patients with this pharmacologically safe agent.
PURPOSE: A composition containing Cuscuta japonica Choisy or RehmanniaglutinosaLibschitz var. purpurea MAKINOandCuscuta japonica Choisyextract is provided to effectively suppress hearing threashold value and to enhance drug compliance. CONSTITUTION: A pharmaceutical composition for preventing or treating hearing loss contains Cuscuta japonica Choisy or Cuscuta japonica Choisy and RehmanniaglutinosaLibschitz var. purpurea MAKINO extract. The hearing loss is noise-induced hearing loss. TheCuscuta japonica Choisy extract is prepared by extracting water, alcohol of C1-C4, or a mixture thereof. Cuscuta japonica Choisy includes Cuscutachinensis Lam., CuscutapentagonaEngelm.,Cuscuta japonica Choisy, or Cuscutaaustralis R. Br.
Participants randomized into the Delayed Delivery arm (n = 150) don't receive access to the app until one month post-baseline. For the RCT portion of the analysis, they will also be assessed at baseline and one month post-baseline (i.e., a pre- and post- prior to app exposure, making them the placebo comparator).
Weight Achievement and Intensive Treatment (Why WAIT) is a 12 -week multidisciplinary program for weight control and intensive diabetes management designed by the Joslin Diabetes Center for application in a multidisciplinary diabetes practice environment. Participants will be enrolled in a 12-week multidisciplinary intensive weight management including diet, exercise, behavioral and educational support. Participants will be enrolled in cohorts of 10-15 participants to encourage group interaction and support. Subjects will choose to come to the Joslin clinic every Tuesday or Wednesday evening for 2 hours. Participants will exercise for an hour and will attend a didactic session in the areas of nutrition, exercise and behavioral modifications.
Participants are required to attend three assessment visits. During these assessments, participants will complete a questionnaire that will ask about their eating patterns, body image, sleep habits, and loneliness and have their height and weight measured. Participants are also required to attend 50-minute yoga classes on Mondays, Wednesdays, and Fridays from 1:25-2:15pm for 10 weeks. The overall time commitment for Yoga Group participants is 3 hours of assessments and 50-minute yoga classes 3X week for 10 weeks.
The investigators propose a new antitumor cell therapy for treating childhood refractory solid tumours. The aim of this study is explore the graft versus tumour effect mediated by allogenic natural killer cells (NKs). NK cell alloreactivity can be predicted by donor killer immunoglobulin-like receptors (KIRs) and human leukocyte antigen (HLA) class I alleles mismatch. Cells without an inhibitory HLA ligand may trigger natural killer cell activation and elimination of those target cells. Reduced risk of relapsed has been described in malignant cancer after haploidentical stem cell transplantation when HLA ligands against the inhibitory KIRs present in the donor were absent in the recipient (KIR-HLA receptor-ligand mismatch). NK alloreactivity could also be obtained by Natural Killer Receptor (NCR), Toll-Like-Receptors (TLRs) and NKG2D receptor stimulation mediated by cytokines or tumour cell lines.
Participants will receive 125 mg/m\^2 NAB and 1000 mg/m\^2 GEM, as an IV infusion once weekly on Days 1, 8, and 15 of each cycle. Each cycle will be of 4-weeks (28 days) with Week 4 of every cycle as a rest week (that is; no treatment will be given). Treatment will continue until documented disease progression or unacceptable toxicity. Dexamethasone 8 mg will be given in each cycle within 2 hours prior to the beginning of each NAB infusion and 8 to 12 hours after the completion of GEM infusion.
The human gastrointestinal system is a complex ecosystem crucial for well-being. During sepsis-induced gut injury, the integrity of the intestinal barrier can be compromised. Lipopolysaccharide (LPS), an endotoxin from Gram-negative bacteria, disrupts the intestinal barrier, contributing to inflammation and various dysfunctions. The current study explores the protective effects of limonene, a natural compound with diverse biological properties, against LPS-induced jejunal injury in mice. Oral administration of limonene at dosages of 100 and 200 mg/kg was used in the LPS mouse model. The Murine Sepsis Score (MSS) was utilized to evaluate the severity of sepsis, while serum levels of urea and creatinine served as indicators of renal function. Our results indicated that LPS injection induced renal function deterioration, evidenced by elevated serum urea and creatinine levels compared to control mice. However, pretreatment with limonene at doses of 100 and 200 mg/kg mitigated this decline in renal function, evidenced from the reduced levels of serum urea and creatinine. Limonene demonstrated anti-inflammatory effects by reducing pro-inflammatory cytokines (TNF-α, IL-1β, COX-2), suppressing the TLR4/NF-κB/AP-1 but not IRF3 signaling pathways, and modulating oxidative stress through Nrf2 activation. The results suggest that limonene holds promise as a potential therapeutic agent for mitigating intestinal inflammation and preserving gastrointestinal health.